Resources
176 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/12/2021 (updated 4/5/2024)
The National Center on Substance Abuse and Child Welfare (NCSACW), a program of the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Administration on Children, Youth and Families (ACYF), prepared this document to support policy makers, administrators, and service providers. The goal of the document is to foster collaborative responses across multiple systems to improve safety, permanency, and well-being outcomes for infants, recovery for their parents, and to meet the needs of families and caregivers.
Posted 4/1/2024 (updated 4/5/2024)
Below is a listing of the sessions that occurred at the 2024 Reverse Site Visit on Friday, March 8, 2024 from 9:45 a.m. - 11:15 a.m. Click on a link to access the session's materials.
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)
Posted 3/29/2024 (updated 4/4/2024)